TY - JOUR
T1 - Barley based gluten free beer – A blessing or an uncontrollable risk?
AU - Cubero-Leon, Elena
AU - Madsen, Charlotte B.
AU - Scherf, Katharina A.
AU - Colgrave, Michelle L.
AU - Nørgaard, Jørgen V.
AU - Anthoni, Minna
AU - Rizou, Katerina
AU - Walker, Michael J.
AU - Sollid, Ludvig M.
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/9/25
Y1 - 2024/9/25
N2 - Recent reports have highlighted that beer labelled “gluten-free”, crafted with enzymatic treatments to remove gluten, may contain polypeptides that could be immunotoxic to individuals with coeliac disease. As strict adherence to a gluten-free diet is the only way to manage this condition, accurate labelling is crucial to those with coeliac disease. This paper aims to discuss the presence, levels and immunogenicity of gluten peptides found in gluten-reduced barley beers. While advances have been made in the detection and quantification of gluten peptides in beer, there are still challenges to the interpretation of gluten measurements as well as to assess whether peptides are immunotoxic in vivo. To make progress, future efforts should involve a combination of in vivo toxicity assessment of the degraded proteins, development of standardised gluten-free production strategies to minimise variability in gluten fragment presence, guidance on how to control the outcome as well as to develop appropriate reference materials and calibrators.
AB - Recent reports have highlighted that beer labelled “gluten-free”, crafted with enzymatic treatments to remove gluten, may contain polypeptides that could be immunotoxic to individuals with coeliac disease. As strict adherence to a gluten-free diet is the only way to manage this condition, accurate labelling is crucial to those with coeliac disease. This paper aims to discuss the presence, levels and immunogenicity of gluten peptides found in gluten-reduced barley beers. While advances have been made in the detection and quantification of gluten peptides in beer, there are still challenges to the interpretation of gluten measurements as well as to assess whether peptides are immunotoxic in vivo. To make progress, future efforts should involve a combination of in vivo toxicity assessment of the degraded proteins, development of standardised gluten-free production strategies to minimise variability in gluten fragment presence, guidance on how to control the outcome as well as to develop appropriate reference materials and calibrators.
KW - Coeliac disease
KW - Gluten quantification
KW - Gluten-free beer
KW - Hydrolysis
KW - Reference materials
KW - Risk assessment
UR - https://www.scopus.com/pages/publications/85204781508
U2 - 10.1016/j.fct.2024.115019
DO - 10.1016/j.fct.2024.115019
M3 - Review article / Perspectives
C2 - 39307344
AN - SCOPUS:85204781508
SN - 0278-6915
VL - 193
JO - Food and Chemical Toxicology
JF - Food and Chemical Toxicology
M1 - 115019
ER -